This page shows the latest ceftazidime news and features for those working in and with pharma, biotech and healthcare.
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization.
aeruginosa. AstraZeneca (AZ) recently secured CHMP backing in Europe for Zavicefta - which combines established cephalosporin antibiotic ceftazidime with new-generation beta lactamase inhibitor avibactam.
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Zavicefta (ceftazidime/avibactam), which combines an established antibiotic with a new drug designed to overcome bacterial resistance. ... In the US, Actavis (now operating
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...